ViraCyte, Inc.
ViraCyte, Inc. is listed today as Kalaris Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2019 | $121 M | No. 2 | $50 to $250 million | equity | SEC | |
| Sep 2018 | $30 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ViraCyte, Inc. chose not to state its revenue in its newest notice of a funding round (May 2019).
SEC Form D · May 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2019
That is all the official record says: ViraCyte, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of ViraCyte, Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Brett R. Hagen | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2020) | SEC Form 3 |
| ElevateBio, LLC | Other | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Jeroen B. Van Beek | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2020) | SEC Form 3 |
| John Robert Wilson | Person | not stated | not stated | Held Series A-3 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Juan Vera | Person | not stated | not stated | Held Series A-3 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 47 investors.
Largest shareholders today
Institutions holding Kalaris Therapeutics, Inc. shares, as of Sep 30, 2026.
- Samsara Biocapital, LLC$37 M54.11%
- RTW Investments, LP$4 M5.46%
- Alyeska Investment Group, L.P.$1 M1.99%
- Siren, L.L.C.$1 M1.50%
- Vanguard Capital Management LLC$1 M1.39%
- Ikarian Capital, LLC$1 M1.04%
- Renaissance Technologies LLC$1 M0.74%
- Verdad Advisers, LP$0 M0.59%
- UBS Group AG$0 M0.46%
- Raymond James Financial Inc$0 M0.43%
- WHI TRUST Co LLC$0 M0.41%
- Woodline Partners LP$0 M0.38%
- Geode Capital Management, LLC$0 M0.33%
- Boothbay Fund Management, LLC$0 M0.27%
- ADAR1 Capital Management, LLC$0 M0.25%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Hallal | Executive officer | May 2019 |
| Vikas Sinha | Executive officer | May 2019 |
| Ansbert Gadicke | Director | May 2019 |
| David Hallal | Director | May 2019 |
| John Wilson | Director | May 2019 |
| Juan Vera | Director | May 2019 |
| Malcom Brenner | Director | May 2019 |
| Morana Jovan-Embiricos | Director | May 2019 |
| Vikas Sinha | Director | May 2019 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.